Breaking News

Samsung Biologics Achieves ISO 37301:2021 Certification

Leading standard for Compliance Management System reflects the company's compliance with organizational governance and laws and regulations.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Samsung Biologics, a global CDMO, has achieved ISO 37301:2021 certification for the first time. The company also renewed certifications for upgraded ISO 27001:2022 and ISO 27017:2015 standards. The certifications were presented by the British Standards Institution (BSI) at Samsung Biologics’ headquarters.   The ISO 37301:2021, a leading standard for Compliance Management System, reflects the company’s compliance with organizational governance and laws and regulations.    The comp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters